Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 3/2011

01-03-2011 | Reviews

Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection

Authors: Tatyana A. Shamliyan, MD, MS, James R. Johnson, MD, Roderick MacDonald, MS, Aasma Shaukat, MD, MPH, Jian-Min Yuan, MD, PhD, Robert L. Kane, MD, Timothy J. Wilt, MD, MPH

Published in: Journal of General Internal Medicine | Issue 3/2011

Login to get access

Abstract

OBJECTIVES

To evaluate the comparative effectiveness of antiviral drugs in adults with chronic hepatitis B monoinfection for evidence-based decision-making.

METHODS

A systematic review of randomized controlled clinical trials (RCTs) published in English. Results after interferon and nucleos(t)ides analog therapies were synthesized with random-effects meta-analyses and number needed to treat (NNT).

RESULTS

Despite sustained improvements in selected biomarkers, no one drug regimen improved all intermediate outcomes. In 16 underpowered RCTs, drug treatments did not reduce mortality, liver cancer, or cirrhosis. Sustained HBV DNA clearance was achieved in one patient when two were treated with adefovir (NNT from 1 RCT = 2 95%CI 1;2) or interferon alfa-2b (NNT from 2 RCTs = 2 95%CI 2;4), 13 with lamivudine (NNT from 1 RCT = 13 95%CI 7;1000), and 11 with peginterferon alfa-2a vs. lamivudine (NNT from 1 RCT = 11 95%CI 7;25). Sustained HBeAg seroconversion was achieved in one patient when eight were treated with interferon alfa-2b (NNT from 2 RCTs = 8 95%CI 5;33) or 10—with peginterferon alfa-2b vs. interferon alfa-2b (NNT from 1 RCT = 10 95%CI 5;1000). Greater benefits and safety after entecavir vs. lamivudine or pegylated interferon alfa-2b vs. interferon alfa-2b require future investigation of clinical outcomes. Adverse events were common and more frequent after interferon. Treatment utilization for adverse effects is unknown.

CONCLUSIONS

Individual clinical decisions should rely on comparative effectiveness and absolute rates of intermediate outcomes and adverse events. Future research should clarify the relationship of intermediate and clinical outcomes and cost-effectiveness of drugs for evidence-based policy and clinical decisions.
Appendix
Available only for authorised users
Literature
1.
Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009;49(5 Suppl):S4–12.PubMedCrossRef
2.
Wilt TJ, Shamliyan T, Shaukat A, et al. Management of chronic hepatitis B. Evid Rep Technol Assess (Full Rep). 2008;174:1–671.
3.
Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S96–102.PubMedCrossRef
4.
Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150(2):111–24.PubMed
5.
Reichen J. ACP Journal Club. Review: evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B. Ann Intern Med. 2009;150(10):JC5–6.PubMed
6.
National Institutes of Health (U.S.). NIH consensus development conference management of hepatitis B. [Bethesda, Md.: National Institutes of Health; 2008: Retieved October 1, 2010 http://​videocast.​nih.​gov/​launch.​asp?​14714 Retrieved October 1, 2010 http://videocast.nih.gov/launch.asp?14712 Retrieved October 1, 2010 http://videocast.nih.gov/launch.asp?14719
7.
Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–84.PubMedCrossRef
8.
Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S103–11.PubMedCrossRef
9.
Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S112–21.PubMedCrossRef
10.
Higgins J, Green S, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley-Blackwell; 2008.CrossRef
11.
Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009;151(3):203–5.PubMed
12.
Slutsky J, Atkins D, Chang S, Sharp BA. AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63(5):481–3.PubMedCrossRef
13.
Helfand M, Balshem H. AHRQ series paper 2: principles for developing guidance: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63(5):484–90.PubMedCrossRef
14.
Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35.PubMedCrossRef
15.
Cochrane Collaboration. The Cochrane library. Retrieved October 1, 2010 from http://​www3.​interscience.​wiley.​com/​cgi-bin/​mrwhome/​106568753/​HOME
16.
United States. Food and Drug Administration. MedWatch. MedWatch online voluntary reporting form (3500). [Rockville, Md.]: Food and Drug Administration, MedWatch; 2002. Retrieved October 1, 2010 from http://​purl.​access.​gpo.​gov/​GPO/​LPS39966 and retrieved October 1, 2010 from http://purl.access.gpo.gov/GPO/LPS81658
17.
Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol. 2007;31(5):504–9.PubMedCrossRef
18.
19.
Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;82(8):967–75.PubMedCrossRef
20.
West S, King V, Carey TS, et al. Systems to rate the strength of scientific evidence. Evid Rep Technol Assess. 2002;47:1–11.
21.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896–900.PubMedCrossRef
22.
Whitehead A. Meta-analysis of Controlled Clinical Trials. Chichester: John Wiley & Sons; 2002.CrossRef
23.
24.
Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. Feb 6 2006.
25.
Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. Biom J. 2006;48(2):271–85.PubMedCrossRef
26.
Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53(2):207–16.PubMedCrossRef
27.
Atkins D, Briss PA, Eccles M, et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res. 2005;5(1):25.PubMedCrossRef
28.
Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38.PubMedCrossRef
29.
Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care. London: NetLibrary, Inc. BMJ Books; 2001.CrossRef
30.
Ebrahim S. The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. Eval Health Prof. 2001;24(2):152–64.PubMedCrossRef
31.
Altman DG. Confidence intervals for the number needed to treat. Br Med J (Clinical research). 1998;317(7168):1309–12.
32.
Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63(5):502–12.PubMedCrossRef
33.
Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80.PubMedCrossRef
34.
Red book 2008 pharmacy’s fundamental reference. 2008 ed. Montvale, N.J.: Thomson; 2008.
35.
You JH, Chan FW. Pharmacoeconomics of entecavir treatment for chronic hepatitis B. Expert Opin Pharmacother. 2008;9(15):2673–81.PubMedCrossRef
36.
Jones J, Shepherd J, Baxter L, et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technol Assess. 2009;13(35):1–172. iii.
37.
Janssen HL, Gerken G, Carreno V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1999;30(1):238–43.PubMedCrossRef
38.
Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46(4):562–8.PubMedCrossRef
39.
Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol. 2001;35(3):406–11.PubMedCrossRef
40.
Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36(1):186–94.PubMedCrossRef
41.
Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002;36(6):1425–30.PubMed
42.
Chung YH, Song BC, Lee GC, et al. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial. Eur J Gastroenterol Hepatol. 2003;15(5):489–93.PubMed
43.
Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003;38(6):818–26.PubMedCrossRef
44.
Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis. 2003;36(12):1516–22.PubMedCrossRef
45.
Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. Eur J Med. 1992;1(7):396–402.PubMed
46.
Robson SC, Brice E, van Rensburg C, Kannemeyer J, Hift RJ, Kirsch RE. Safety and efficacy of interferon alpha-2b following prednisone withdrawal in the treatment of chronic viral hepatitis B. A case-controlled, randomised study. S Afr Med J. 1992;82(5):317–20.PubMed
47.
Akarca US, Ersoz G, Gunsar F, et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther. 2004;9(3):325–34.PubMed
48.
Jang MK, Chung YH, Choi MH, et al. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol. 2004;19(12):1363–8.PubMedCrossRef
49.
Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992;102(6):2091–7.PubMed
50.
Economou M, Manolakopoulos S, Trikalinos TA, et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol. 2005;11(37):5882–7.PubMed
51.
Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005;100(11):2463–71.PubMedCrossRef
52.
Shi M, Wang RS, Zhang H, et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother. 2006;58(5):1031–5.PubMedCrossRef
53.
Scotto G, Palumbo E, Fazio V, Cibelli DC, Saracino A, Angarano G. Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant. Infez Med. 2006;14(3):145–51.PubMed
54.
Lu HY, Zhuang LW, Yu YY, et al. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol. 2007;13(20):2878–82.PubMed
55.
Akyuz F, Kaymakoglu S, Demir K, et al. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastroenterol Belg. 2007;70(1):20–4.PubMed
56.
Perez V, Tanno H, Villamil F, Fay O. Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol. 1990;11(Suppl 1):S113–7.PubMedCrossRef
57.
Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol. 1990;11(Suppl 1):S133–6.PubMedCrossRef
58.
Muller R, Baumgarten R, Markus R, et al. Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol. 1990;11(Suppl 1):S137–40.PubMedCrossRef
59.
Waked I, Amin M, Abd el Fattah S, Osman LM, Sabbour MS. Experience with interferon in chronic hepatitis B in Egypt. J Chemother. 1990;2(5):310–8.PubMed
60.
Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323(5):295–301.PubMedCrossRef
61.
Zarski JP, Causse X, Cohard M, Cougnard J, Trepo C. A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. J Hepatol. 1994;20(6):735–41.PubMedCrossRef
62.
Reichen J, Bianchi L, Frei PC, Male PJ, Lavanchy D, Schmid M. Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. Swiss Association for the Study of the Liver. J Hepatol. 1994;20(2):168–74.PubMedCrossRef
63.
Di Bisceglie AM, Fong TL, Fried MW, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol. 1993;88(11):1887–92.PubMed
64.
Perez V, Findor J, Tanno H, Sorda J. A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up. Gut. 1993;34(2 Suppl):S91–4.PubMedCrossRef
65.
Muller R, Baumgarten R, Markus R, et al. Low dose alpha interferon treatment in chronic hepatitis B virus infection. Gut. 1993;34(2 Suppl):S97–8.PubMedCrossRef
66.
Lopez-Alcorocho JM, Bartolome J, Cotonat T, Carreno V. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy. J Viral Hepat. 1997;4(Suppl 1):27–32.PubMedCrossRef
67.
Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997;26(6):1621–5.PubMedCrossRef
68.
Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol. 1998;28(6):923–9.PubMedCrossRef
69.
Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56(5):699–705.PubMedCrossRef
70.
Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis. 2003;10(4):298–305.CrossRef
71.
Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206–17.PubMedCrossRef
72.
Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95.PubMedCrossRef
73.
Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol. 2007;41(5):513–7.PubMedCrossRef
74.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348(9):800–7.PubMedCrossRef
75.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352(26):2673–81.PubMedCrossRef
76.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–51.PubMedCrossRef
77.
Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808–16.PubMedCrossRef
78.
Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006;44(1):108–16.PubMedCrossRef
79.
Westland C, Delaney Wt, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003;125(1):107–16.PubMedCrossRef
80.
Westland CE, Yang H, Delaney WEt, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003;38(1):96–103.PubMedCrossRef
81.
Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66(3):1153–8.PubMedCrossRef
82.
Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126(1):81–90.PubMedCrossRef
83.
Akyildiz M, Gunsar F, Ersoz G, et al. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci. 2007;52(12):3444–7.PubMedCrossRef
84.
Peters MG, Hann HWH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126(1):91–101.PubMedCrossRef
85.
Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147(11):745–54.PubMed
86.
Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. American J Gastroenterol. 2006;101(2):297–303.CrossRef
87.
Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–9.PubMedCrossRef
88.
Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46(2):388–94.PubMedCrossRef
89.
ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology. 2006;44(3):721–7.PubMedCrossRef
90.
Flink HJ, Hansen BE, Heathcote EJ, et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006;101(11):2523–9.PubMed
91.
van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005;21(9):1163–71.PubMedCrossRef
92.
Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut. 2005;54(11):1604–9.PubMedCrossRef
93.
van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006;26(4):399–405.PubMedCrossRef
94.
Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology. 2005;41(6):1357–64.PubMedCrossRef
95.
Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005;142(4):240–50.PubMed
96.
Chan HL, Tse AM, Zhang MD, et al. Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment Pharmacol Ther. 2006;23(12):1703–11.PubMedCrossRef
97.
Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44(4):541–8.PubMedCrossRef
98.
Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354(10):1011.PubMedCrossRef
99.
Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–10.PubMedCrossRef
100.
Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123(6):1831–8.PubMedCrossRef
101.
Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129(4):1198–209.PubMedCrossRef
102.
Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–49.PubMedCrossRef
103.
Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437–44.PubMedCrossRef
104.
Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528–36.PubMed
105.
Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001;35(6):749–55.PubMedCrossRef
106.
Ke CZ, Chen Y, Gong ZJ, et al. Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment. World J Gastroenterol. 2006;12(25):4061–3.PubMed
107.
Yuen MF, Chow DH, Tsui K, et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005;21(7):841–9.PubMedCrossRef
108.
109.
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31.PubMedCrossRef
110.
Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119(1):172–80.PubMedCrossRef
111.
Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33(6):1527–32.PubMedCrossRef
112.
Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105–17.PubMedCrossRef
113.
Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341(17):1256–63.PubMedCrossRef
114.
Honkoop P, de Man RA, Niesters HG, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepatitis. 1998;5(5):307–12.CrossRef
115.
Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997;113(4):1258–63.PubMedCrossRef
116.
Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345–53.PubMed
117.
Yao G, Wang B, Cui Z, Yao J, Zeng M. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J (Engl). 1999;112(5):387–91.
118.
Kim YJ, Kim BG, Jung JO, Yoon JH, Lee HS. High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol. 2006;41(3):240–9.PubMedCrossRef
119.
Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology. 1999;29(3):889–96.PubMedCrossRef
120.
Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357(25):2576–88.PubMedCrossRef
121.
Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47(2):447–54.PubMedCrossRef
122.
Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442–55.PubMedCrossRef
123.
Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61–8.PubMedCrossRef
124.
Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology. 2009;49(5 Suppl):S85–95.PubMedCrossRef
125.
McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA. 2000;284(1):79–84.PubMedCrossRef
126.
McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA. 2000;283(21):2829–36.PubMedCrossRef
127.
Chalmers I. Well informed uncertainties about the effects of treatments. Br Med J (Clinical research). 2004;328(7438):475–6.CrossRef
128.
Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49(5 Suppl):S174–84.PubMedCrossRef
129.
130.
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(5 Suppl):S185–95.PubMedCrossRef
131.
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. Feb 2009;50(2):227-242.
132.
Belongia EA, Costa J, Gareen IF, et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements. 2008;25(2):1–29.PubMed
133.
Dusheiko GM. Cost-effectiveness of oral treatments for chronic hepatitis B. J Hepatol. Aug 6 2009.
134.
Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J Hepatol. May 20 2009.
Metadata
Title
Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection
Authors
Tatyana A. Shamliyan, MD, MS
James R. Johnson, MD
Roderick MacDonald, MS
Aasma Shaukat, MD, MPH
Jian-Min Yuan, MD, PhD
Robert L. Kane, MD
Timothy J. Wilt, MD, MPH
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 3/2011
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1569-5

Other articles of this Issue 3/2011

Journal of General Internal Medicine 3/2011 Go to the issue

Healing Arts: Materia Medica

Sounds of Haiti

Original Research

Geriatric Conditions Develop in Middle-Aged Adults with Diabetes

Original Research

Measuring Faculty Reflection on Adverse Patient Events: Development and Initial Validation of a Case-Based Learning System

Original Research

Racial/Ethnic Disparities in Exercise and Dietary Behaviors of Middle-Aged and Older Adults

Original Research

Validation of Self-Reported Health Literacy Questions Among Diverse English and Spanish-Speaking Populations

Original Research

Presence and Correlates of Racial Disparities in Adherence to Colorectal Cancer Screening Guidelines
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits